These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 29791894)

  • 1. Highly Tumorigenic Diffuse Large B Cell Lymphoma Cells Are Produced by Coculture with Stromal Cells.
    Lin Z; Chen B; Wu T; Xu X
    Acta Haematol; 2018; 139(4):201-216. PubMed ID: 29791894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-κB activation.
    Tsai HJ; Shih NY; Kuo SH; Cheng AL; Lin HY; Chen TY; Chang KC; Lin SF; Chang JS; Chen LT
    Leuk Lymphoma; 2015; 56(9):2674-82. PubMed ID: 25535814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma.
    Li L; Yang W; Pan Y; Ye R; Wang Y; Li S; Jiang H; Zhang Q; Wang X; Yan J
    Leuk Lymphoma; 2024 Jul; 65(7):895-910. PubMed ID: 38497543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma.
    Stelling A; Wu CT; Bertram K; Hashwah H; Theocharides APA; Manz MG; Tzankov A; Müller A
    Blood Adv; 2019 Oct; 3(20):3020-3032. PubMed ID: 31648327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma.
    Bongero D; Paoluzzi L; Marchi E; Zullo KM; Neisa R; Mao Y; Escandon R; Wood K; O'Connor OA
    Leuk Lymphoma; 2015; 56(10):2945-52. PubMed ID: 25860245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces.
    Sangaletti S; Iannelli F; Zanardi F; Cancila V; Portararo P; Botti L; Vacca D; Chiodoni C; Di Napoli A; Valenti C; Rizzello C; Vegliante MC; Pisati F; Gulino A; Ponzoni M; Colombo MP; Tripodo C
    EBioMedicine; 2020 Nov; 61():103055. PubMed ID: 33096480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma.
    Feng L; Xu X; Zhao K
    Leuk Res; 2021 Dec; 111():106708. PubMed ID: 34536775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway.
    Chang S; Li B; Xie Y; Wang Y; Xu Z; Jin S; Yu D; Wang H; Lu Y; Zhang Y; Ma R; Huang C; Lai W; Wu X; Zhu W; Shi J
    Neoplasia; 2022 Jan; 24(1):50-61. PubMed ID: 34890905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate.
    Holien T; Olsen OE; Misund K; Hella H; Waage A; Rø TB; Sundan A
    Eur J Haematol; 2013 Oct; 91(4):339-46. PubMed ID: 23869695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma.
    Xu ZZ; Wang WF; Fu WB; Wang AH; Liu ZY; Chen LY; Guo P; Li JM
    Leuk Lymphoma; 2014 May; 55(5):1151-7. PubMed ID: 23841505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide.
    Xu PP; Sun YF; Fang Y; Song Q; Yan ZX; Chen Y; Jiang XF; Fei XC; Zhao Y; Leboeuf C; Li B; Wang CF; Janin A; Wang L; Zhao WL
    Sci Rep; 2017 Aug; 7(1):7433. PubMed ID: 28785100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma.
    Habiel DM; Krepostman N; Lilly M; Cavassani K; Coelho AL; Shibata T; Elenitoba-Johnson K; Hogaboam CM
    Oncotarget; 2016 Dec; 7(50):83514-83529. PubMed ID: 27835864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.
    Mathur R; Sehgal L; Havranek O; Köhrer S; Khashab T; Jain N; Burger JA; Neelapu SS; Davis RE; Samaniego F
    Haematologica; 2017 Feb; 102(2):373-380. PubMed ID: 27742770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
    Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
    Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of chemokines in diffuse large B-cell lymphoma: a systematic review and future insights.
    Huang Q; Liu F; Shen J
    Future Oncol; 2019 Apr; 15(12):1385-1395. PubMed ID: 30880459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.
    Lv X; Feng L; Ge X; Lu K; Wang X
    J Exp Clin Cancer Res; 2016 Jul; 35(1):106. PubMed ID: 27364124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
    Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J
    J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactive oxygen species mediate oridonin-induced apoptosis through DNA damage response and activation of JNK pathway in diffuse large B cell lymphoma.
    Xu ZZ; Fu WB; Jin Z; Guo P; Wang WF; Li JM
    Leuk Lymphoma; 2016; 57(4):888-98. PubMed ID: 26415087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.
    Schuhmacher B; Rengstl B; Döring C; Bein J; Newrzela S; Brunnberg U; Kvasnicka HM; Vornanen M; Küppers R; Hansmann ML; Hartmann S
    Oncotarget; 2016 Nov; 7(44):72197-72210. PubMed ID: 27708232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.
    Sun X; Li B; Xie B; Xu Z; Chang G; Tao Y; Zhang Y; Chang S; Wang Y; Yu D; Xie Y; Li T; Wang H; Chen G; Hu L; Hou J; Zhang Y; Xiao W; Gao L; Shi J; Zhu W
    Cell Death Dis; 2017 Oct; 8(10):e3111. PubMed ID: 29022919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.